BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cacabelos R. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Metab Toxicol 2020;16:673-701. [PMID: 32520597 DOI: 10.1080/17425255.2020.1779700] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Cacabelos R. Pharmacogenetics for Improving Efficacy and Safety in Drug Development and for Reducing Costs in Alzheimer’s Disease. CPPM 2022;19:3-6. [DOI: 10.2174/1875692119666220603154831] [Reference Citation Analysis]
2 Cacabelos R. Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment. Alzheimer's Disease Drug Development 2022. [DOI: 10.1017/9781108975759.036] [Reference Citation Analysis]
3 Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Personalized Management and Treatment of Alzheimer’s Disease. Life 2022;12:460. [DOI: 10.3390/life12030460] [Reference Citation Analysis]
4 Cacabelos R. What have we learnt from past failures in Alzheimer's disease drug discovery? Expert Opin Drug Discov 2022;:1-15. [PMID: 35129021 DOI: 10.1080/17460441.2022.2033724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2573-6_13] [Reference Citation Analysis]
6 Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. IJMS 2021;22:13302. [DOI: 10.3390/ijms222413302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Uliassi E, de Oliveira AS, de Camargo Nascente L, Romeiro LAS, Bolognesi ML. Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer's Disease. Molecules 2021;26:5441. [PMID: 34576912 DOI: 10.3390/molecules26185441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cacabelos R, Carrera I, Martínez-Iglesias O, Cacabelos N, Naidoo V. What is the gold standard model for Alzheimer's disease drug discovery and development? Expert Opin Drug Discov 2021;:1-26. [PMID: 34330186 DOI: 10.1080/17460441.2021.1960502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
9 Rastegari A, Safavi M, Vafadarnejad F, Najafi Z, Hariri R, Bukhari SNA, Iraji A, Edraki N, Firuzi O, Saeedi M, Mahdavi M, Akbarzadeh T. Synthesis and evaluation of novel arylisoxazoles linked to tacrine moiety: in vitro and in vivo biological activities against Alzheimer's disease. Mol Divers 2021. [PMID: 34273065 DOI: 10.1007/s11030-021-10248-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Chou PS, Huang LC, Hour TC, Yen CW, Yang YH. Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease. J Formos Med Assoc 2021:S0929-6646(21)00241-2. [PMID: 34120801 DOI: 10.1016/j.jfma.2021.05.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cacabelos R, Carril JC, Corzo L, Fernández-Novoa L, Pego R, Cacabelos N, Cacabelos P, Alcaraz M, Tellado I, Naidoo V. Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease. Pharmaceuticals (Basel) 2021;14:366. [PMID: 33920985 DOI: 10.3390/ph14040366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Prasher P, Sharma M. Medicinal Chemistry of Indane and Its Analogues: A Mini Review. ChemistrySelect 2021;6:2658-77. [DOI: 10.1002/slct.202100177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
13 Pohanka M, Zakova J. A Smartphone Camera Colorimetric Assay of Acetylcholinesterase and Butyrylcholinesterase Activity. Sensors (Basel) 2021;21:1796. [PMID: 33807562 DOI: 10.3390/s21051796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Auxtero MD, Chalante S, Abade MR, Jorge R, Fernandes AI. Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction. Pharmaceutics 2021;13:124. [PMID: 33478035 DOI: 10.3390/pharmaceutics13010124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Zhang Q, Hao C, Miao Y, Yun Y, Sun X, Pan Y, Sun J, Wang X. Design and synthesis of benzyl aminocoumarin and its anti-Alzheimer's activity. New J Chem 2021;45:17287-17300. [DOI: 10.1039/d1nj02950a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Bhatt S, Puli L, Patil CR. Role of reactive oxygen species in the progression of Alzheimer's disease. Drug Discov Today 2021;26:794-803. [PMID: 33306995 DOI: 10.1016/j.drudis.2020.12.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]